Prifinium bromide
Based on 1 Customer Validation
Prifinium bromide is an anticholinergic drug with anticholinergic and antispasmodic activities, and it exhibits oral activity. Prifinium bromide competitively antagonizes cholinergic receptors and relieves symptoms of spasm or hypermotility in the digestive and urinary tracts, with its anticholinergic activity representing the core mechanism underlying the inhibition of bladder smooth muscle contraction. Prifinium bromide can be used in research related to spasms and diverticular disease.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.41%
- CAS No.: 4630-95-9
- 화학식: C22H28BrN
- 분자량:386.37
-
보관:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
Biological Activity
제품 설명
In Vitro
Prifinium bromide inhibits carbamoylcholine chloride (HY-B1208)-induced contraction of isolated guinea pig detrusor muscle, but exerts almost no effect on contractions induced by electrical stimulation, KCl or BaCl2[1].
Prifinium bromide exhibits anticholinergic activity in isolated guinea pig ileum, with a relative potency of 0.45 compared with Atropine (HY-B1205)[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 4630-95-9
-
Appearance Solid
-
분자량 386.37
-
화학식 C22H28BrN
-
Color White to off-white
-
SMILES
CC1[N+](CC)(CC/C1=C(C2=CC=CC=C2)\C3=CC=CC=C3)CC.[Br-]
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
용액&용해도
In Vitro:
DMSO : 100 mg/mL (258.82 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (12.94 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 5 mg/mL (12.94 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (290 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Terai T, et al. Effects of the anticholinergic drug prifinium bromide on urinary bladder contractions in rat in vivo and in guinea-pig in vitro. Arzneimittelforschung. 1991;41(4):417-420. [Content Brief]
[2]. Ohki S, et al. Synthesis of Pyrrolidine Derivatives with Pharmacological Activity. XII. Synthesis and Anticholinergic Activity of 1,1-Dialkyl-3-diphenylmethylene-2,4-dimethylpyrrolidinium Halides. Chem Pharm Bull. 1986;34(9):3606-3613. [Content Brief]
[3]. Sasaki D, et al. Anti-spasmodic effect of prifinium bromide on the proximal and distal colon in patients with diverticular disease. Gastroenterol Jpn. 1981;16(4):344-349. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.5882 mL | 12.9410 mL | 25.8819 mL | 64.7048 mL |
| 5 mM | 0.5176 mL | 2.5882 mL | 5.1764 mL | 12.9410 mL | |
| 10 mM | 0.2588 mL | 1.2941 mL | 2.5882 mL | 6.4705 mL | |
| 15 mM | 0.1725 mL | 0.8627 mL | 1.7255 mL | 4.3137 mL | |
| 20 mM | 0.1294 mL | 0.6470 mL | 1.2941 mL | 3.2352 mL | |
| 25 mM | 0.1035 mL | 0.5176 mL | 1.0353 mL | 2.5882 mL | |
| 30 mM | 0.0863 mL | 0.4314 mL | 0.8627 mL | 2.1568 mL | |
| 40 mM | 0.0647 mL | 0.3235 mL | 0.6470 mL | 1.6176 mL | |
| 50 mM | 0.0518 mL | 0.2588 mL | 0.5176 mL | 1.2941 mL | |
| 60 mM | 0.0431 mL | 0.2157 mL | 0.4314 mL | 1.0784 mL | |
| 80 mM | 0.0324 mL | 0.1618 mL | 0.3235 mL | 0.8088 mL | |
| 100 mM | 0.0259 mL | 0.1294 mL | 0.2588 mL | 0.6470 mL |
Prifinium bromide Related Classifications
HY-122086 Related Classifications
Powered by Bioz